Voloridge Investment Management
IPXL

Voloridge Investment Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Voloridge Investment Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,708
Closed -$271K – 364
2015
Q3 		$271K Buy
+7,708
New +$347K 0.01% 258

Other funds holding IPXL

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Voloridge Investment Management's IPXL Position: Q4 2015 in Review

Voloridge Investment Management sold out of Impax Laboratories, Inc. (IPXL) in Q4 2015, closing a stake of 7,708 shares — an estimated $271K sold.

Voloridge Investment Management first reported a position in IPXL in Q3 2015 and held it in 1 quarter. The position peaked at $271K in Q3 2015. 196 funds tracked by Wall St. Rank hold IPXL as of Q4 2015.

  • Voloridge Investment Management reported no remaining Impax Laboratories, Inc. position as of Q4 2015 after selling out during the quarter.
  • Voloridge Investment Management sold 7,708 Impax Laboratories, Inc. shares in Q4 2015, an estimated $271K.
  • Voloridge Investment Management first reported a position in Impax Laboratories, Inc. in Q3 2015 and held it in 1 quarter.
  • Voloridge Investment Management's Impax Laboratories, Inc. position peaked at $271K in Q3 2015.
  • 196 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2015.

Based on Voloridge Investment Management's 13F filing for Q4 2015, filed 16 Feb 2016.